You are here

Meeting Highlights

Second European Post-Chicago Melanoma Meeting 2012

Walter Alexander

After the immunotherapeutic agent ipilimumab (Yervoy) demonstrated a 4-month increase in the survival of patients with metastatic melanoma, it was approved in March 2011. That event ended a 13-year drought in FDA approvals for melanoma since the approval of interleukin-2 (IL-2, Proleukin) in 1998. Although IL-2 did extend survival, it is rarely used because of toxicity.

With interest piqued by new developments in melanoma therapy, 480 oncologists attended the inaugural European Post-Chicago Melanoma Meeting last year. This year’s Second European Post-Chicago Melanoma meeting (June 21 and 22, 2012) similarly welcomed 481 specialists to reviews and analyses of research on CTLA-4 antibodies, selective kinase inhibitors, new vaccination approaches, and other innovative agents under development for intratumoral and systemic therapies.

Selected sessions on targeted and chemotherapeutic agents, immunotherapies, and the continuing role of chemotherapy are presented here.


  1. Trefzer U. BREAK-2: A phase IIA trial of the selective BRAF kinase inhibitor GSK 2118436 in patients with BRAF (V600E/K) positive metastatic melanoma (LBA1 1). 8th International Congress for the Society of Melanoma ResearchTampa, Fla.November 9–13, 2011
  2. Patel SP, Bedikian AY, Papadopoulos NE, et al. Ipilimumab plus temozolomide in metastatic melanoma (Abstract 8579). American Society of Clinical Oncology (ASCO) meetingChicagoJune 3–7, 2011J Clin Oncol 2011;29;(Suppl.):
  3. Di Giacomo AM, Acierto PA, Fonsatti E, et al. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial (Abstract TPS230). American Society of Clinical Oncology (ASCO) meetingChicagoJune 3–7, 2011J Clin Oncol 2011;29;(Suppl):
  4. Kaufman HL, Bines SD. OPTIM trial: A phase II trial of an oncolytic herpes virus encoding GM-CSF for unresectable state II or IV melanoma. Fut Oncol 2010;6;(6):941–949.
  5. Beck S. Conference Report. ASCO: Programmed death 1 (PD-1) inhibitor one of the ‘most exciting’ new melanoma agents. June 52012;Available at: Accessed August 7, 2012.
  6. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17;(9):2745–2751.
  7. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27;(17):2323–2830.
  8. Flaherty LE, Moon J, Atkins MB, et al. Phase III trial of highdose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG (Abstract 8504). American Society of Clinical Oncology (ASCO) meetingChicagoJune 2–5, 2012J Clin Oncol 2012;30;(Suppl.):
  9. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526.